BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pegtarazimod readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pegtarazimod\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06343792-1538@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pegtarazimod: Phase 2 readout est. (NCT06343792)
DESCRIPTION:Pegtarazimod\, phase 2.\nStudy: Safety\, PK\, PD\, Dosing\, and
  Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Stero
 id-Refractory Acute Graft-versus-Host Disease\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peg
 tarazimod#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06343792
URL:https://assetmemo.bio/drug/pegtarazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05778188-1538@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pegtarazimod: Phase 2/3 readout est. (NCT05778188)
DESCRIPTION:Pegtarazimod\, phase 2/3.\nStudy: A Study to Evaluate the Safet
 y\, Tolerability\, Pharmacokinetics\, and Efficacy of RLS-0071 in Newborns
  With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therap
 eutic Hypothermia\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pegtarazimod#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05778188
URL:https://assetmemo.bio/drug/pegtarazimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
